The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage

Nicola Scichilone, Fabiano Di Marco, Fulvio Braido, Pierachille Santus, Blasi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Lower respiratory tract infections (LRTIs), including pneumonia and acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD), are among the most common diagnoses in both outpatient and inpatient settings. Due to the burden of LRTIs healthcare providers must adopt practices focused on improving outcomes with the aim to reduce treatment failure and antibiotic resistances. Moreover, the role of acute and chronic infection in the pathogenesis of COPD has received considerable attention, since chronic infection can contribute to airways inflammation and COPD progression. This review discusses the role of cefditoren for the treatment of LRTIs, compared with the definition of "appropriate" of the WHO as "the cost-effective use of antimicrobials which maximizes clinical therapeutic effect while minimizing both drug-related toxicity and the development of antimicrobial resistance".
Original languageEnglish
Pages (from-to)321-332
Number of pages12
JournalEuropean Review for Medical and Pharmacological Sciences
Volume18
Publication statusPublished - 2014

Fingerprint

Community-Acquired Infections
Respiratory Tract Infections
Chronic Obstructive Pulmonary Disease
Pneumonia
Therapeutic Uses
Microbial Drug Resistance
Infection
Drug-Related Side Effects and Adverse Reactions
Treatment Failure
Health Personnel
Disease Progression
Inpatients
Outpatients
Therapeutics
Inflammation
Costs and Cost Analysis
cefditoren

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

@article{b848fe18acf04865ae6e9bdf8d980a85,
title = "The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage",
abstract = "Lower respiratory tract infections (LRTIs), including pneumonia and acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD), are among the most common diagnoses in both outpatient and inpatient settings. Due to the burden of LRTIs healthcare providers must adopt practices focused on improving outcomes with the aim to reduce treatment failure and antibiotic resistances. Moreover, the role of acute and chronic infection in the pathogenesis of COPD has received considerable attention, since chronic infection can contribute to airways inflammation and COPD progression. This review discusses the role of cefditoren for the treatment of LRTIs, compared with the definition of {"}appropriate{"} of the WHO as {"}the cost-effective use of antimicrobials which maximizes clinical therapeutic effect while minimizing both drug-related toxicity and the development of antimicrobial resistance{"}.",
author = "Nicola Scichilone and {Di Marco}, Fabiano and Fulvio Braido and Pierachille Santus and Blasi",
year = "2014",
language = "English",
volume = "18",
pages = "321--332",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",

}

TY - JOUR

T1 - The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage

AU - Scichilone, Nicola

AU - Di Marco, Fabiano

AU - Braido, Fulvio

AU - Santus, Pierachille

AU - Blasi, null

PY - 2014

Y1 - 2014

N2 - Lower respiratory tract infections (LRTIs), including pneumonia and acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD), are among the most common diagnoses in both outpatient and inpatient settings. Due to the burden of LRTIs healthcare providers must adopt practices focused on improving outcomes with the aim to reduce treatment failure and antibiotic resistances. Moreover, the role of acute and chronic infection in the pathogenesis of COPD has received considerable attention, since chronic infection can contribute to airways inflammation and COPD progression. This review discusses the role of cefditoren for the treatment of LRTIs, compared with the definition of "appropriate" of the WHO as "the cost-effective use of antimicrobials which maximizes clinical therapeutic effect while minimizing both drug-related toxicity and the development of antimicrobial resistance".

AB - Lower respiratory tract infections (LRTIs), including pneumonia and acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD), are among the most common diagnoses in both outpatient and inpatient settings. Due to the burden of LRTIs healthcare providers must adopt practices focused on improving outcomes with the aim to reduce treatment failure and antibiotic resistances. Moreover, the role of acute and chronic infection in the pathogenesis of COPD has received considerable attention, since chronic infection can contribute to airways inflammation and COPD progression. This review discusses the role of cefditoren for the treatment of LRTIs, compared with the definition of "appropriate" of the WHO as "the cost-effective use of antimicrobials which maximizes clinical therapeutic effect while minimizing both drug-related toxicity and the development of antimicrobial resistance".

UR - http://hdl.handle.net/10447/98601

M3 - Article

VL - 18

SP - 321

EP - 332

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

ER -